Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 424
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary Appendix C Acronyms AGISAR Advisory Group on Integrated Surveillance of Antimicrobial Resistance AGP antimicrobial growth promoters AIDS acquired immune deficiency syndrome AMR antimicrobial resistance APUA Alliance for the Prudent Use of Antibiotics Ara-C Arabinofuranosyl Cytidine ARI antimicrobial-resistant infection AST antimicrobial susceptibility testing ATCC American Type Culture Collection BARDA Biomedical Advanced Research and Development Authority CAC Codex Alimentarius Commission CA-MRSA community-associated methicillin-resistant Staphylococcus aureus CAP community acquired pneumonia CDC Centers for Disease Control and Prevention CF cystic fibrosis CI confidence interval CLSI Clinical and Laboratory Standards Institute CTX-M cefotaximase DANMAP Danish Integrated Antimicrobial Resistance Monitoring and Research Programme
OCR for page 425
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary DDT dichlorodiphenyltrichloroethane DNA deoxyribonucleic acid DRG diagnosis-related group ECDC European Centre for Disease Prevention and Control EMEA European Medicines Agency ESBL extended-spectrum β-lactamase FAO Food and Agriculture Organization of the United Nations FDA Food and Drug Administration GMP good manufacturing practice HHS United States Department of Health and Human Services Hib Haemophilus influenza type b HIV human immunodeficiency virus ICE integrative conjugative element ICH International Conference on Harmonization IDSA Infectious Diseases Society of America IMCI Integrated Management of Childhood Illness IMPACT International Medical Products Anti-Counterfeiting Taskforce IND investigational new drug IOM Institute of Medicine IPO initial public offering KPC Klebsiella pneumoniae carbapenemase MALDI-TOF matrix-assisted laser desorption ionization time of flight MDR multidrug resistant MIC minimal inhibitory concentration MRSA methicillin-resistant Staphylococcus aureus MSSA methicillin-susceptible Staphylococcus aureus NDA new drug application NHSN National Healthcare Safety Network NIH National Institutes of Health NTA non-therapeutic antimicrobial OIE World Organisation for Animal Health PAMTA Preservation of Antibiotics for Medical Treatment Act PDR pan-drug resistant
OCR for page 426
Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies - Workshop Summary PK-PD pharmacokinetic and pharmacodynamic PVL Panton–Valentine leukocidin RNA ribonucleic acid R&D research and development ROAR Reservoirs of Antibiotic Resistance ROS reactive oxygen species SCCmec staphylococcal chromosome cassette mec STAAR Act Strategies to Address Antimicrobial Resistance Act TA toxin-antitoxin TB tuberculosis UV ultraviolet VICP Vaccine Injury Compensation Program VISA vancomycin-intermediate Staphylococcus aureus VRE vancomycin-resistant enterococci VRSA vancomycin-resistant Staphylococcus aureus WHA World Health Assembly WHO World Health Organization XDR extensively drug-resistant